Ming Hou

9.7k total citations
249 papers, 5.3k citations indexed

About

Ming Hou is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Ming Hou has authored 249 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 198 papers in Hematology, 61 papers in Immunology and 54 papers in Genetics. Recurrent topics in Ming Hou's work include Platelet Disorders and Treatments (184 papers), Blood groups and transfusion (85 papers) and Autoimmune Bullous Skin Diseases (45 papers). Ming Hou is often cited by papers focused on Platelet Disorders and Treatments (184 papers), Blood groups and transfusion (85 papers) and Autoimmune Bullous Skin Diseases (45 papers). Ming Hou collaborates with scholars based in China, United States and Sweden. Ming Hou's co-authors include Jun Peng, Yu Hou, Xinguang Liu, Xuebin Ji, Ping Qin, Li-Zhen Li, Lin Wang, Daoxin Ma, Linlin Shao and Hans Wadenvik and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ming Hou

238 papers receiving 5.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming Hou China 39 3.8k 1.2k 1.1k 914 622 249 5.3k
Jun Peng China 38 2.7k 0.7× 959 0.8× 1.1k 1.0× 683 0.7× 962 1.5× 158 4.5k
Itaru Matsumura Japan 39 2.0k 0.5× 456 0.4× 1.1k 1.0× 1.2k 1.3× 2.5k 4.1× 216 5.5k
Changgeng Ruan China 32 1.6k 0.4× 226 0.2× 663 0.6× 367 0.4× 856 1.4× 202 3.1k
Sentot Santoso Germany 49 5.5k 1.5× 275 0.2× 1.8k 1.7× 402 0.4× 1.3k 2.0× 229 8.5k
Adam S. Asch United States 31 991 0.3× 398 0.3× 1.0k 0.9× 367 0.4× 1.7k 2.7× 98 4.6k
Jean‐François Rossi France 36 3.2k 0.9× 926 0.8× 1.5k 1.3× 693 0.8× 2.7k 4.4× 110 6.4k
Hiroaki Niiro Japan 43 713 0.2× 500 0.4× 2.8k 2.5× 636 0.7× 1.3k 2.1× 145 5.4k
Thomas Luther Germany 39 2.3k 0.6× 122 0.1× 649 0.6× 704 0.8× 1.7k 2.7× 84 5.5k
Harvey R. Gralnick United States 35 2.0k 0.5× 466 0.4× 432 0.4× 689 0.8× 560 0.9× 92 3.8k
J W Adamson United States 32 2.7k 0.7× 129 0.1× 996 0.9× 1.4k 1.5× 750 1.2× 70 4.7k

Countries citing papers authored by Ming Hou

Since Specialization
Citations

This map shows the geographic impact of Ming Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Hou more than expected).

Fields of papers citing papers by Ming Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Hou. The network helps show where Ming Hou may publish in the future.

Co-authorship network of co-authors of Ming Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Ming Hou. A scholar is included among the top collaborators of Ming Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming Hou. Ming Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Fengjiao, Qiuyu Guo, Lin Han, et al.. (2025). CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia. British Journal of Haematology. 206(5). 1430–1442. 1 indexed citations
2.
Li, Qian, Geneviève Marcoux, Johan Rebetz, et al.. (2024). Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP). Autoimmunity Reviews. 23(12). 103677–103677. 9 indexed citations
3.
Sun, Lu, Juan Wang, Chenglu Yuan, et al.. (2024). Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial. Blood. 144(17). 1791–1799. 2 indexed citations
4.
Mei, Heng, Hu Zhou, Ming Hou, et al.. (2023). Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China. Research and Practice in Thrombosis and Haemostasis. 7(6). 102158–102158. 9 indexed citations
5.
6.
Liu, Qiang, Qi Feng, Xiaorong Yang, et al.. (2023). Obesity is associated with poor outcomes of corticosteroid treatment in patients with primary immune thrombocytopenia. British Journal of Haematology. 203(2). 295–303. 2 indexed citations
7.
Liu, Yan, Yin Wang, Cheng Zhang, et al.. (2022). HDAC3 single‐nucleotide polymorphism rs2530223 is associated with increased susceptibility and severity of primary immune thrombocytopenia. International Journal of Laboratory Hematology. 44(5). 875–882. 2 indexed citations
8.
Li, Ranran, Shuwen Wang, Linlin Shao, et al.. (2022). Association of metformin treatment and outcome in adult patients with ITP and pre‐existing T2DM. British Journal of Haematology. 197(3). 367–372. 2 indexed citations
9.
Ni, Xiaofei, Lingjun Wang, Haoyi Wang, et al.. (2022). Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia. Blood. 140(26). 2818–2834. 12 indexed citations
10.
Han, Panpan, Yu Hou, Yajing Zhao, et al.. (2021). Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood. 138(8). 674–688. 47 indexed citations
11.
Yu, Yafei, Yu Hou, Yajing Zhao, et al.. (2021). Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. British Journal of Haematology. 194(1). 191–194. 10 indexed citations
12.
Yu, Tianshu, Lingjun Wang, Xiaofei Ni, et al.. (2021). Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP). Blood. 138(Supplement 1). 3172–3172. 8 indexed citations
13.
Hua, Mingqiang, Ju Li, Chunyan Wang, et al.. (2019). Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia. Thrombosis Research. 177. 70–78. 31 indexed citations
14.
Xu, Miao, June Li, Miguel A. D. Neves, et al.. (2018). GPIbα is required for platelet-mediated hepatic thrombopoietin generation. Blood. 132(6). 622–634. 50 indexed citations
15.
16.
17.
Qin, Ping, Shan Xiao, Hai Zhou, et al.. (2017). A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 130(9). 1097–1103. 75 indexed citations
18.
Amash, Alaa, Lin Wang, Yawen Wang, et al.. (2016). CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor– and Complement Receptor 3–Dependent Mechanisms. The Journal of Immunology. 196(8). 3331–3340. 22 indexed citations
19.
Wei, Yu, Xuebin Ji, Yawen Wang, et al.. (2015). High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 127(3). 296–302. 145 indexed citations
20.
Zeng, Qingshu, Lingyan Zhu, Lili Tao, et al.. (2011). Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti‐platelet GPIIbIIIa versus GPIbα antibodies. American Journal of Hematology. 87(2). 206–208. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Peng Breakdown of academic impact, for papers by Itaru Matsumura Breakdown of academic impact, for papers by Changgeng Ruan Breakdown of academic impact, for papers by Sentot Santoso Breakdown of academic impact, for papers by Adam S. Asch Breakdown of academic impact, for papers by Jean‐François Rossi Breakdown of academic impact, for papers by Hiroaki Niiro Breakdown of academic impact, for papers by Thomas Luther Breakdown of academic impact, for papers by Harvey R. Gralnick Breakdown of academic impact, for papers by J W Adamson
Rankless by CCL
2026